secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001193125-25-200078
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Daraxonrasib shows 35% ORR in 2L PDAC, 55% in 1L combo; Phase 3 planned
-----------------------------------------------------------------------

- 2L PDAC: ORR 29-35% (RAS G12X and broader mutant), DCR 92-95%, median PFS 8.1-8.5 mo, median OS 13.1-15.6 mo.
- 1L monotherapy (300 mg): ORR 47%, DCR 89% among 38 evaluable patients as of July 28, 2025 cutoff.
- 1L combo daraxonrasib 200 mg + gemcitabine/nab-paclitaxel: ORR 55%, DCR 90% in 31 evaluable patients.
- Grade ≥3 TRAEs: 34% monotherapy (2L), 35% (1L), 58% combo; most common rash, GI; 0% discontinuation in 2L.
- Company plans to initiate RASolute 303, a global Phase 3 trial in 1L PDAC comparing daraxonrasib ± GnP vs GnP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312525200078/0001193125-25-200078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312525200078/d947102d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-200078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer